Guanosine 5'-diphosphate-13C10 (dilithium)

CAT:
804-HY-113066S1
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Guanosine 5'-diphosphate-13C10 (dilithium) - image 1

Guanosine 5'-diphosphate-13C10 (dilithium)

  • UNSPSC Description:

    Guanosine 5'-diphosphate-13C10 (GDP-13C10) dilithium is 13C-labeled Guanosine 5'-diphosphate (HY-113066). Guanosine 5'-diphosphate (GDP) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K+ channel. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulates the interleukin-6 (IL-6)/stat-3 pathway. Guanosine 5'-diphosphate can be used in the research of inflammation, such as anemia of inflammation (AI).
  • Target Antigen:

    Endogenous Metabolite; Isotope-Labeled Compounds; Potassium Channel
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Others
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/guanosine-5-diphosphate-13c10-dilithium.html
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=P(OP(O[Li])(O[Li])=O)(O)O[13CH][13C@@H]1[13C@@](O)[13C@@](O)[13C@H](N2[13C](N=[13C](N)N[13C]3=O)=[13C]3N=[13CH]2)O1
  • Molecular Weight:

    461.97
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]S Kajioka, et al. Guanosine diphosphate activates an adenosine 5'-triphosphate-sensitive K+ channel in the rabbit portal vein. J Physiol. 1991 Dec;444:397-418.|[3]Angmo S, et al. Identification of Guanosine 5'-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway. Sci Rep. 2017 Jan 5;7:40097.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    No Development Reported